|Videos|July 22, 2016

What Benefits Can Therapy Animals Have in the Healthcare Setting?

Gonzalo Bearman, MD, MPH, hospital epidemiologist, Virginia Commonwealth University, discusses the benefits of animals visits to healthcare settings.

Gonzalo Bearman, MD, MPH, hospital epidemiologist, Virginia Commonwealth University, discusses the benefits of animals visits to healthcare settings.

Interview Transcript (slightly modified for readability)

“Bodies of literature suggest that there is some benefit from having an animal visit the healthcare setting. That benefit to the patient isn’t necessarily like a shorter length of stay or improved patient overall satisfaction. But it does impact things like perception of pain, loneliness, [and] depression. It may even have some impact on some neurohumoral things, which might improve overall outcomes.

There is some potential benefit, and of course there’s a risk. That risk is small, it’s real, but it’s small, but it can likely be engineered out so that the risk is acceptable, given the benefits.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.